Q2 EPS Estimates for TerrAscend Lowered by Ventum Cap Mkts

Key Points

• Ventum Capital Markets has revised its Q2 2025 earnings estimate for TerrAscend Corp., projecting a loss of ($0.02) per share, down from the previous estimate of ($0.01).
• TerrAscend reported Q2 earnings of ($0.03) per share, missing analyst expectations by ($0.01) and experiencing a negative net margin of 25.27%.
• Despite the earnings downgrade, Atb Capital Markets upgraded TerrAscend from a "hold" rating to a "strong-buy" rating earlier this year.

TerrAscend Corp. (OTCMKTS:TSNDF - Free Report) - Equities research analysts at Ventum Cap Mkts reduced their Q2 2025 earnings per share estimates for TerrAscend in a report issued on Wednesday, August 6th. Ventum Cap Mkts analyst A. Semple now forecasts that the company will earn ($0.02) per share for the quarter, down from their prior estimate of ($0.01). The consensus estimate for TerrAscend's current full-year earnings is ($0.14) per share. Ventum Cap Mkts also issued estimates for TerrAscend's Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.09) EPS and FY2026 earnings at ($0.04) EPS.

Separately, Atb Cap Markets raised TerrAscend from a "hold" rating to a "strong-buy" rating in a research report on Thursday, May 8th.

TerrAscend Stock Up 8.8%

Shares of TSNDF stock traded up $0.04 on Friday, hitting $0.55. 855,846 shares of the stock were exchanged, compared to its average volume of 550,775. The company has a current ratio of 1.31, a quick ratio of 0.70 and a debt-to-equity ratio of 1.42. The firm has a market capitalization of $169.80 million, a P/E ratio of -1.35 and a beta of 1.39. The business has a 50-day moving average of $0.34 and a 200 day moving average of $0.40. TerrAscend has a fifty-two week low of $0.23 and a fifty-two week high of $1.75.

TerrAscend (OTCMKTS:TSNDF - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). TerrAscend had a negative net margin of 40.86% and a negative return on equity of 21.15%. The business had revenue of $65.01 million during the quarter, compared to analyst estimates of $64.87 million.

About TerrAscend

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names.